JP2005508610A - 異種タンパク質の製造に有用なプラス鎖ｒｎａウイルスゲノムに由来するレプリコン - Google Patents

異種タンパク質の製造に有用なプラス鎖ｒｎａウイルスゲノムに由来するレプリコン Download PDF

Info

Publication number
JP2005508610A
JP2005508610A JP2002592486A JP2002592486A JP2005508610A JP 2005508610 A JP2005508610 A JP 2005508610A JP 2002592486 A JP2002592486 A JP 2002592486A JP 2002592486 A JP2002592486 A JP 2002592486A JP 2005508610 A JP2005508610 A JP 2005508610A
Authority
JP
Japan
Prior art keywords
rna
protein
self
molecule according
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002592486A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508610A5 (enExample
Inventor
エスクリオウ，ニコラス
デア ワーフ，シルヴィー ヴァン
ヴィグヌッツィ，マルコ
ジャーバウド，シルヴィー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of JP2005508610A publication Critical patent/JP2005508610A/ja
Publication of JP2005508610A5 publication Critical patent/JP2005508610A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32211—Cardiovirus, e.g. encephalomyocarditis virus
    • C12N2770/32241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/32243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2002592486A 2001-05-23 2002-05-23 異種タンパク質の製造に有用なプラス鎖ｒｎａウイルスゲノムに由来するレプリコン Withdrawn JP2005508610A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29251501P 2001-05-23 2001-05-23
PCT/IB2002/002810 WO2002095023A2 (en) 2001-05-23 2002-05-23 Replicons derived from positive strand rna virus genomes useful for the production of heterologous proteins

Publications (2)

Publication Number Publication Date
JP2005508610A true JP2005508610A (ja) 2005-04-07
JP2005508610A5 JP2005508610A5 (enExample) 2006-01-05

Family

ID=23124993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002592486A Withdrawn JP2005508610A (ja) 2001-05-23 2002-05-23 異種タンパク質の製造に有用なプラス鎖ｒｎａウイルスゲノムに由来するレプリコン

Country Status (8)

Country Link
US (2) US20030077251A1 (enExample)
EP (1) EP1390517A2 (enExample)
JP (1) JP2005508610A (enExample)
KR (1) KR20040007567A (enExample)
CN (1) CN1575339A (enExample)
AU (1) AU2002339603A1 (enExample)
CA (1) CA2443258A1 (enExample)
WO (1) WO2002095023A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011521654A (ja) * 2008-06-04 2011-07-28 インスティトゥート フュア ヴィルスクランクハイテン ウント イムンプロフィラクセ Ｒｎａに基づくウイルスベクター系を提供するペスチウイルスレプリコン
JP2013538569A (ja) * 2010-08-31 2013-10-17 ノバルティス アーゲー 免疫原をコードするｒｎａの送達のための小さなリポソーム
JP2023528300A (ja) * 2020-05-29 2023-07-04 オンコラス， インコーポレイテッド 封入されたｒｎａレプリコンおよび使用方法
WO2024225374A1 (ja) * 2023-04-25 2024-10-31 慎治 小笠原 インフルエンザウイルスのＲｄＲｐによるｖＲＮＡの転写及び／又は複製を制御する方法、並びにその利用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012542A (es) 2003-06-05 2006-02-08 Wyeth Corp Composiciones inmunogenicas que comprenden vectores de replicon del virus de la encefalitis equina venezolana y antigenos de la proteina del paramixovirus.
KR100788894B1 (ko) 2005-12-09 2007-12-27 한국전자통신연구원 확대된 서비스 영역을 제공하는 직교 주파수 분할 다중방식의 무선 랜 송수신 시스템 및 그 방법
WO2008103755A1 (en) * 2007-02-20 2008-08-28 Mayo Foundation For Medical Education And Research Treating cancer with viral nucleic acid
US9909192B2 (en) * 2007-06-01 2018-03-06 Universidad De Barcelona Control for virus detection assays based on reverse-transcription polymerase chain reaction
ES2543222T3 (es) * 2008-09-24 2015-08-17 Ribomic Inc. Aptámero para NGF y uso del mismo
PL2590676T3 (pl) 2010-07-06 2017-02-28 Glaxosmithkline Biologicals Sa Wirionopodobne cząstki dostarczające dla autoreplikujących się cząsteczek rna
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
DK3243526T3 (da) 2010-07-06 2020-02-17 Glaxosmithkline Biologicals Sa Levering af rna til at udløse flere immunsignalveje
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
BR112013000244A2 (pt) 2010-07-06 2016-05-17 Novartis Ag lipossomas com lipídeos apresentando pka vantajoso para administração de rna
RS63315B1 (sr) 2010-08-31 2022-07-29 Glaxosmithkline Biologicals Sa Pegilovani lipozomi za isporuku rnk koja kodira imunogen
CA2814386C (en) 2010-10-11 2019-08-20 Novartis Ag Antigen delivery platforms
CA3198966A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Cleavable lipids
US20140206753A1 (en) 2011-06-08 2014-07-24 Shire Human Genetic Therapies, Inc. Lipid nanoparticle compositions and methods for mrna delivery
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
EP4115875A1 (en) * 2011-07-06 2023-01-11 GlaxoSmithKline Biologicals S.A. Liposomes having useful n:p ratio for delivery of rna molecules
CN114231562A (zh) * 2021-12-15 2022-03-25 中国科学院武汉病毒研究所 一种表达荧光素酶基因的淋巴脉络丛脑膜炎病毒及其构建方法和应用
CN114317563B (zh) * 2021-12-17 2023-09-05 华南理工大学 提高基因表达的rna复制子及其应用
CN117070464A (zh) * 2022-05-16 2023-11-17 上海行深生物科技有限公司 蛋白包裹自复制rna及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125896D0 (en) * 1991-12-05 1992-02-05 Almond Jeffrey W Bicistronic viruses
WO1994029472A2 (en) * 1993-06-03 1994-12-22 Institut Pasteur Mengovirus as a vector for expression of foreign polypeptides
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011521654A (ja) * 2008-06-04 2011-07-28 インスティトゥート フュア ヴィルスクランクハイテン ウント イムンプロフィラクセ Ｒｎａに基づくウイルスベクター系を提供するペスチウイルスレプリコン
JP2013538569A (ja) * 2010-08-31 2013-10-17 ノバルティス アーゲー 免疫原をコードするｒｎａの送達のための小さなリポソーム
JP2023528300A (ja) * 2020-05-29 2023-07-04 オンコラス， インコーポレイテッド 封入されたｒｎａレプリコンおよび使用方法
WO2024225374A1 (ja) * 2023-04-25 2024-10-31 慎治 小笠原 インフルエンザウイルスのＲｄＲｐによるｖＲＮＡの転写及び／又は複製を制御する方法、並びにその利用

Also Published As

Publication number Publication date
KR20040007567A (ko) 2004-01-24
WO2002095023A2 (en) 2002-11-28
CN1575339A (zh) 2005-02-02
AU2002339603A1 (en) 2002-12-03
US20050118566A1 (en) 2005-06-02
WO2002095023A3 (en) 2003-05-08
US20030077251A1 (en) 2003-04-24
CA2443258A1 (en) 2002-11-28
EP1390517A2 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
JP2005508610A (ja) 異種タンパク質の製造に有用なプラス鎖ｒｎａウイルスゲノムに由来するレプリコン
US10570416B2 (en) TC-83-derived alphavirus vectors, particles and methods
KR101518309B1 (ko) 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
US8961995B2 (en) Methods and compositions for alphavirus replicons
JP2023551982A (ja) マルチシストロン性ｒｎａワクチン及びその使用
JPWO2012053646A1 (ja) ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム／ブーストワクチン用ウイルスベクター
ES2902787T3 (es) Vacunas de ADNi y procedimientos para utilizar las mismas
Morrow et al. Recombinant viruses as vectors for mucosal immunity
US20160279229A9 (en) Viral Vaccine Vectors
WO2002083896A2 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
JP2025516332A (ja) 疾患の治療のためのレプリコン組成物およびそれを使用する方法
EP4493196A2 (en) Novel rna and dna technology for vaccination against alphaviruses and other emerging and epidemic viruses
HK1084692B (en) Improved alphavirus replicons and helper constructs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050512

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20050922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050922